Burzynski clinic

From Ganfyd

Revision as of 21:08, 8 January 2012 by Penglish (Talk | contribs)
Jump to: navigation, search

The Burzynski clinic is a clinic in Texas, USA, run by the eponymous Dr Stanislaw Burzynski. The clinic uses "antineoplastons" to treat neoplastic diseases such as various forms of cancer.

The treatment has been criticised as unproven; and the clinic has been alleged to have been charging patients large amounts of money to enter trials of the drug. It has been alleged that the Texas Medical Board has instituted proceedings against Stanslaw Burzynski which could lead to the revocation of his medical licence. In 1997 a federal prosecution of Dr Burzynski failed and was called "a government witch hunt" by a juror in the court action with the Lancet calling for greater tolerance of alternative medicine[1]. In November 2011 somebody called Marc Stephens, who claimed to represent the clinic, issued threats of legal action against critics including a 17 year-old Welsh school boy called Rhys Morgan (Wikipedia page), and Andy Lewis. These threats generated a Streisand effect, with many bloggers repeating the criticisms and the threats. On 29 November 2011 the clinic released a statement with a list of citations that it claimed rebutted the criticisms, disassociated the clinic from Mr Stephens, and yet appeared to confirm that it believed that the blogs were libellous.

The issues have probably been as well summarised by Tauriq Moosa as by anybody.[2]

They can be summarised as follows:

  • People who have been told they have an incurable form of cancer that is likely to kill them or their child may feel desperate. It is completely understandable that they will clutch at straws.
  • Cure-providers may offer treatments that are not proven effective. (Professor Bishop has provided some guidance as to whether something is a pioneering new treatment, or "quackery").[3] Providers may genuinely believe that they have found a cure, and offer the treatment in good faith; or they may be acting cynically, exploiting desperate, vulnerable people for profit.
  • People who have invested emotionally and financially in the treatment may feel upset and personally affronted to see it criticised, no matter how reasonably: they may feel that criticism of the provider is criticism of them, and their choice to invest in the treatment. They may respond by attacking the critics.
  • Providers and their supporters may attempt to suppress criticism of the treatment. The UK libel laws, which are notoriously slanted in favour of plaintiffs, can all too easily be used to suppress criticism.
  • On this occasion, attempts by supporters of Burzyinski's clinic to threaten critics were widely publicised, following the publication of a newspaper article that was uncritical of the treatment.


Contents

Articles about patients raising funds to go to the Burzynski clinic

The Observer published a follow-up article on 4 November 2011, which has been criticised (e.g. by Andy Lewis and Skeptical Humanities).

Some of the blogs and articles which have criticised the Burzynski clinic and its antineoplaston treatment

The most complete list of such web sites is probably

A selection of others follows:

Burzynski clinic statement of 29 November 2011

Burzynski clinic statement of 29 November, p1 Burzynski clinic statement of 29 November, p2 Burzynski clinic statement of 29 November, p3

Articles about antineoplastons or by Stanislaw Burzynski

These have also been considered by other bloggers, such as:


PubMed citations

Searching PubMed for "Burzynski" and "antineoplastons" finds 37 articles (on 30/11/11):

  • Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther. 2006 Mar;5(1):40-7. PMID: 16484713.[5]
  • Burzynski SR, Weaver RA, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov V. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther. 2005 Jun;4(2):168-77. PMID: 15911929.[6]
  • Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D. 2004;5(6):315-26. PMID: 15563234.[7]
  • Burzynski SR, Lewy RI, Weaver R, Janicki T, Jurida G, Khan M, Larisma CB, Paszkowiak J, Szymkowski B.Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme. Integr Cancer Ther. 2004 Sep;3(3):257-61. PMID: 15312271.[8]
  • Hammer MR, Jonas WB. Managing social conflict in complementary and alternative medicine research: the case of antineoplastons. Integr Cancer Ther. 2004 Mar;3(1):59-65. PMID: 15035877.[9]
  • Burzynski SR. The present state of antineoplaston research (1). Integr Cancer Ther. 2004 Mar;3(1):47-58. Review. PMID: 15035876.[10]
  • Burzynski SR, Lewy RI, Weaver RA, Axler ML, Janicki TJ, Jurida GF, Paszkowiak JK, Szymkowski BG, Khan MI, Bestak M. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D. 2003;4(2):91-101. PMID: 12718563.[11]
  • Badria F, Mabed M, Khafagy W, Abou-Zeid L. Potential utility of antineoplaston A-10 levels in breast cancer. Cancer Lett. 2000 Jul 3;155(1):67-70. PMID: 10814881.[12]
  • Burzynski SR. Efficacy of antineoplastons A10 and AS2-1. Mayo Clin Proc. 1999 Jun;74(6):641-2. No abstract available. PMID: 10377942.[13]
  • Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H. Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. Kurume Med J. 1996;43(2):137-47. PMID: 8755117.[14]
  • Burzynski SR. Potential of antineoplastons in diseases of old age. Drugs Aging. 1995 Sep;7(3):157-67. Review. No abstract available. PMID: 8535046.[15]
  • Sołtysiak-Pawłuczuk D, Burzyński SR. Cellular accumulation of antineoplaston AS21 in human hepatoma cells. Cancer Lett. 1995 Jan 6;88(1):107-12. PMID: 7850766.[16]
  • Tsuda H, Hara H, Eriguchi N, Nishida H, Yoshida H, Kumabe T, Sugita Y. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J. 1995;42(4):241-9. PMID: 8667595.[17]
  • Juszkiewicz M, Chodkowska A, Burzynski SR, Mlynarczyk M, Kleinrok Z. The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. Drugs Exp Clin Res. 1995;21(4):153-6. PMID: 8529528.[18]
  • Juszkiewicz M, Chodkowska A, Burzynski SR, Feldo M, Majewska B, Kleinrok Z. The influence of antineoplaston A5 on the central dopaminergic structures. Drugs Exp Clin Res. 1994;20(4):161-7. PMID: 7813388.[19]
  • Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res. 1990;16(7):361-9. PMID: 2152694.[20]
  • Hendry LB, Muldoon TG, Burzynski SR, Copland JA, Lehner AF. Stereochemical modelling studies of the interaction of antineoplaston A10 with DNA. Drugs Exp Clin Res. 1987;13 Suppl 1:77-81. PMID: 3569020.[21]
  • Liau MC, Szopa M, Burzynski B, Burzynski SR. Chemo-surveillance: a novel concept of the natural defence mechanism against cancer. Drugs Exp Clin Res. 1987;13 Suppl 1:71-6. PMID: 3569019.[22]
  • Liau MC, Szopa M, Burzynski B, Burzynski SR. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy. Drugs Exp Clin Res. 1987;13 Suppl 1:61-70. PMID: 3569018.[23]
  • Khalid M, Burzynski SR.N,N'-disubstituted L-isoglutamines as novel cancer chemotherapeutic agents.' Drugs Exp Clin Res. 1987;13 Suppl 1:57-60. PMID: 3569017.[24]
  • Kampalath BN, Liau MC, Burzynski B, Burzynski SR. Chemoprevention by antineoplaston A10 of benzo(a)pyrene-induced pulmonary neoplasia. Drugs Exp Clin Res. 1987;13 Suppl 1:51-5. PMID: 3569016.[25]
  • Ashraf AQ, Liau MC, Kampalath BN, Burzynski SR. Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats. Drugs Exp Clin Res. 1987;13 Suppl 1:45-50. PMID: 3569015.[26]
  • Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res. 1987;13 Suppl 1:37-43. PMID: 3569014.[27]
  • Lee SS, Burzynski SR. Tissue culture and animal toxicity studies of antineoplaston A5. Drugs Exp Clin Res. 1987;13 Suppl 1:31-5. PMID: 3569013.[28]
  • Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res. 1987;13 Suppl 1:17-29. PMID: 3569012.[29]
  • Lee SS, Mohabbat MO, Burzynski SR. In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3. Drugs Exp Clin Res. 1987;13 Suppl 1:13-6. PMID: 3569011[30]
  • Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res. 1987;13 Suppl 1:1-11. PMID: 3569010[31]
  • Liau MC, Burzynski SR. Altered methylation complex isozymes as selective targets for cancer chemotherapy. Drugs Exp Clin Res. 1986;12 Suppl 1:77-86. PMID: 3743383[32]
  • Burzynski SR, Mohabbat MO. Chronic animal toxicity studies on antineoplaston A2. Drugs Exp Clin Res. 1986;12 Suppl 1:73-5. PMID: 3743382.[33]
  • Lehner AF, Burzynski SR, Hendry LB. 3-Phenylacetylamino-2,6-piperidinedione, a naturally-occurring peptide analogue with apparent antineoplastic activity, may bind to DNA. Drugs Exp Clin Res. 1986;12 Suppl 1:57-72. PMID: 3743381.[34]
  • Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res. 1986;12 Suppl 1:47-55. PMID: 3743380[35]
  • Ashraf AQ, Liau MC, Mohabbat MO, Burzynski SR. Preclinical studies on antineoplaston A10 injections. Drugs Exp Clin Res. 1986;12 Suppl 1:37-45. PMID: 3743379[36]
  • Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res. 1986;12 Suppl 1:25-35. PMID: 3743378[37]
  • Burzynski SR. Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res. 1986;12 Suppl 1:17-24. PMID: 3743377.[38]
  • Burzynski SR, Mohabbat MO, Lee SS. Preclinical studies on antineoplaston AS2-1 and antineoplaston AS2-5.” Drugs Exp Clin Res. 1986;12 Suppl 1:11-6. PMID: 3743376.[39]
  • Burzynski SR. Antineoplastons: history of the research (I). Drugs Exp Clin Res. 1986;12 Suppl 1:1-9. Review. PMID: 3527634.[40]
  • Burzynski SR, Stolzmann Z, Szopa B, Stolzmann E, Kaltenberg OP. Antineoplaston A in cancer therapy. (I). Physiol Chem Phys. 1977;9(6):485-500. PMID: 275868.[41]

References in Burzynski clinic letter

The letter from the clinic reproduced above includes "...a list of publications and abstracts providing the results of the FDA approved clinical trials since 2006 which demonstrate the treatment's efficacy on a wide variety of brain tumors." A text version is included below.

These articles should provide good Journal Club material. See e.g. ganfyd's page on critical appraisal. Registered medical practitioners may register as ganfyd authors (if they have not already done so), and post the conclusions of their journal clubs here.

The references in the letter

The references in the letter appear to have been scanned and OCRd - partially corrected text below.

  1. (1) Burzynski, S.R. Treatments for Astrocytic Tumors in Chiìdren: Current and Emerging Strategies. Pediatric Drugs 2006;8:167-178.[42] According to The Twentyfirst Floor, this journal has no impact factor. According to joshtriska, in a response to blag hag the paper is: "A longish review of treatment methods for astrocytic tumors. Antineoplastons are mentioned as being “under investigation” or “promising” in clinical trials, and some survival rates are mentioned. However, references are only to conference abstracts (mostly the ones below), a patent from 1995, his annual report to the FDA, and an entry in a compilation of papers called “Brain cancer research: progress” by Nova Science Publishers that I cannot seem to find."
  2. (2)Burzynski, S.R., Janicki, T.J., Weaver, RA., Burzynski, B. Targeted therapy with Antineoplastons A10 and of high grade, recurrent, and progressive breínstem gliome. Integrative Cancer Therapies 2006; 5(1):40­-47.[43] According to The Twentyfirst Floor, this journal speciaises in alternative and complementary therapies. According to joshtriska, in a response to blag hag the paper is: "A report on 18 patients with “High-Grade, Recurrent, and Progressive Brainstem Glioma” picked from 4 of his clinical trials. The conclusion states that typically less than 10% of patients with this condition survive 2 years, but in his group 22% (or four whole people) survived past 5 years. The conclusion also states that “Because a small number of patients have been evaluated, a larger study is required to confirm these results”. No kidding!"
  3. (3)Burzynski, SR. Recent clinical trials in diffuse intrinsic brainstem glioma. Cancer Therapy 2007;5, 379-390. (Does not appear to be listed in PubMed.) According to The Twentyfirst Floor, this is a review article, not a scientific study, and it is published in a very strange online journal, with no apparent impact factor and numerous pages which return 404 errors. It also contains a weird, extraneous, link on its “home” page to a conspiracy theory style YouTube video. According to joshtriska, in a response to blag hag the paper is: "A review paper, not a study. Antineoplastons are mentioned and a line of data from one of Burzynski’s trials is included in a table. The discussion states that the data concerning antineoplastons was from from conference abstracts, and not peer-reviewed." See zacharybos' comments on the journal Cancer Therapy in a response to blag hag
  4. (4)Burzynski, SR., Weaver, R.A., Janicki, T.J., Jufida, G.F., Szymkowskì, B,G., Kubove, E. Phase II studies of Antineoplastons A10 and AS 2-1 (ANP) in chiìdren with newly diagnosed diffuse, intrinsic brainstem gliomas. Neuro-Oncology 2007;9:206. (Does not appear to be listed in PubMed.) According to The Twentyfirst Floor, this is a conference abstract. According to blag hag the the Journal of Neuro-Oncology has a relatively high impact factor of 5.483, which makes it 24 out of 184 in Oncology. However, when blag hag did a search at the journal web site she found "Burzynski has not published a single paper in this journal. Every single citation is an abstract from a presentation made at a conference. For those of you not in academia, we like to hold conferences where people can present their research and network. However, you’re allowed to present preliminary results that haven’t been published yet. Any scientist can submit abstracts in order to speak at conferences, and if that single paragraph sounds interesting, you get to give a talk. It’s pretty much impossible to judge how legitimate research is from an abstract (or presentation) alone, and some conferences are not competitive at all when it comes to who gets to speak – they have plenty of spaces to accept all presenters. Journals often act as archives for conferences they’re affiliated with, and will list those abstracts... This means that none of Burzynski’s research from this journal has actually been peer-reviewed by the journal. The fact that he never actually published this data says a lot. Seriously – if you legitimately found something that helped cure cancer, prestigious journals would be tripping over themselves to have you publish in them. The fact that you can’t publish your research anywhere except in the occasional bottom-of-the-barrel shady journal means your research is terrible." According to joshtriska, in a response to blag hag the paper is: "Conference abstract. A report on 20 children in several clinical trials."
  5. (5)Burzynskì, SR., Weaver, R., Szymkowski, B. A case report of a complete response and 20-year survival of a patient with a recurrent diffuse intrinsic braînstem anaplastic astrooytoma. Neuro-Oncology 2007;9:536. According to The Twentyfirst Floor, this is a conference abstract. According to joshtriska, in a response to blag hag the paper is: "Conference abstract. A report on a single patient."
  6. (6)Burzynskí, S., Weaver, R., Janíckì, T., Szymkowskí, B., Walczak, M., Burzynskí, G. Phase ii study of antìneoplastons A10 and infusions (ANP) in patients with recurrent anaplastic astrocytorna. Neuro-Oncology 2008;10:1067. According to The Twentyfirst Floor, this is a conference abstract. According to joshtriska, in a response to blag hag the paper is: "Conference abstract. A report on 20 adults from a clinical trial."
  7. (7)Burzynski, SR., Weaver, R., Janicki, T., Waîczak, M., Szymkowski, B., Samuel, S. Phase II study of antìneopiastons A10 and AS2-1 (ANP) in children with optic pathway gliorna: A preliminary report. Neuro­Oncoiogy 2008;10:450. According to The Twentyfirst Floor, this is a conference abstract. According to joshtriska, in a response to blag hag the paper is: "Conference abstract. A preliminary report on 12 children in several clinical trials."
  8. (8)Burzynski, S., Weaver, R., Janicki, T., Burzynski, G., Samuel, S., Szymkowski, B. Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma: A preliminary report. Neuro­Oncology 2008; 10:821. According to The Twentyfirst Floor, this is a conference abstract. According to joshtriska, in a response to blag hag the paper is: "Conference abstract. A preliminary report on 20 adults from a clinical trial."
  9. (9)Weaver, RA., Szymkowski, B., Burzynski, SR. Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem giioma (DBSG) treated with antineoplastons (ANP). Neuro-Oncology 2009;11:923. According to The Twentyfirst Floor, this is a conference abstract. According to joshtriska, in a response to blag hag the paper is: "Conference abstract. A report on a single 10-year-old patient."
  10. (10)Burzynski, SR., Janicki, T.J., Weaver, RA., Szymkowskì, B., Burzynskâ, G.S. Phase II study of antineoplastons A10 and AS2~1 in patients with brainstem glioma: Protocol BC-BT-11. Neuro-Oncology 2009;11:951 According to The Twentyfirst Floor, this is a conference abstract. According to joshtriska, in a response to blag hag the paper is: "Conference abstract. A report on 28 patients from a clinical trial."
  11. (11)Ogata, Y., Shirouzu, K., Matono, M., Ushìjima, M., Uchida, S., Tsuda, H. Randomized phase H study of hepatic arterial infusion with or without antíneoplastons as adjuvant therapy after hepatectomy for liver metastases from colorectal cancer. Ann Oncol 2010;21:viii221 According to The Twentyfirst Floor, this is a conference abstract. According to joshtriska, in a response to blag hag the paper is: "Conference abstract from the 35th ESMO Congress in Milan, Italy, 8–12 October 2010. From the session on colorectal cancer. A small phase II randomized study of 65 post-hepatectomy patients split into two groups and given hepatic arterial infusion chemotherapy with one group given antineoplastons in addition. The group with antineoplastons had a higher cancer-specific survival rate (no numbers are given in the abstract), similar disease-free survival rate, and higher rates of single organ recurrance and re-surgical treatment."
  12. (12)Burzynski, SR, Weaver, RA., Janicki, T., E, Szymkowski, B., Aceiar, S.S., Burzynski, G.S. A phase II study of antineoplaston A10 and injections in children with low­grade astrocytomas. Neuro-Oncology 2010;12(6):ii95. According to The Twentyfirst Floor, this is a conference abstract. According to joshtriska, in a response to blag hag the paper is: "Conference abstract. A report on 17 children from a clinical trial."
  13. (13)Burzynski, SR, Weaver, RA., Janickì, T.J., Burzynski, G.S., Szymkowskî, B., Aceiar, S.S. OT-15. Preliminary results of a phase Il study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas. Neuro~OncoIogy 2010;12(SuppI. 4):iv72. According to The Twentyfirst Floor, this is a conference abstract. According to joshtriska, in a response to blag hag the paper is: "Conference abstract. A preliminary report on 13 adults from a clinical trial."

References

  1. Lessons from antineoplaston. Lancet. 1997 Mar 15; 349(9054):741.
  2. Tauriq Moosa. The Burzynski Clinic Problem. Big Think blog. 2011 (December 3). Last viewed 2011 (December 5).
  3. D Bishop. Pioneering treatment or quackery? How to decide. BishopBlog. 2011 (4 December). Last viewed 2011 (4 December).
  4. Keir Liddle. BBC promoting funding for Quackery? 2011 (31 August). Last viewed 2011 (14 December).
  5. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integrative cancer therapies. 2006 Mar; 5(1):40-7.(Link to article – subscription may be required.)
  6. Burzynski SR, Weaver RA, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov V. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integrative cancer therapies. 2005 Jun; 4(2):168-77.(Link to article – subscription may be required.)
  7. Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs in R&D. 2004; 5(6):315-26.
  8. Burzynski SR, Lewy RI, Weaver R, Janicki T, Jurida G, Khan M, Larisma CB, Paszkowiak J, Szymkowski B. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme. Integrative cancer therapies. 2004 Sep; 3(3):257-61.(Link to article – subscription may be required.)
  9. Hammer MR, Jonas WB. Managing social conflict in complementary and alternative medicine research: the case of antineoplastons. Integrative cancer therapies. 2004 Mar; 3(1):59-65.(Link to article – subscription may be required.)
  10. Burzynski SR. The present state of antineoplaston research (1). Integrative cancer therapies. 2004 Mar; 3(1):47-58.(Link to article – subscription may be required.)
  11. Burzynski SR, Lewy RI, Weaver RA, Axler ML, Janicki TJ, Jurida GF, Paszkowiak JK, Szymkowski BG, Khan MI, Bestak M. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs in R&D. 2003; 4(2):91-101.
  12. Badria F, Mabed M, Khafagy W, Abou-Zeid L. Potential utility of antineoplaston A-10 levels in breast cancer. Cancer letters. 2000 Jul 3; 155(1):67-70.
  13. Burzynski SR. Efficacy of antineoplastons A10 and AS2-1. Mayo Clinic proceedings. Mayo Clinic. 1999 Jun; 74(6):641-2.
  14. Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H. Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. The Kurume medical journal. 1996; 43(2):137-47.
  15. Burzynski SR. Potential of antineoplastons in diseases of old age. Drugs & aging. 1995 Sep; 7(3):157-67.
  16. Sołtysiak-Pawłuczuk D, Burzyński SR. Cellular accumulation of antineoplaston AS21 in human hepatoma cells. Cancer letters. 1995 Jan 6; 88(1):107-12.
  17. Tsuda H, Hara H, Eriguchi N, Nishida H, Yoshida H, Kumabe T, Sugita Y. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. The Kurume medical journal. 1995; 42(4):241-9.
  18. Juszkiewicz M, Chodkowska A, Burzynski SR, Mlynarczyk M, Kleinrok Z. The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. Drugs under experimental and clinical research. 1995; 21(4):153-6.
  19. Juszkiewicz M, Chodkowska A, Burzynski SR, Feldo M, Majewska B, Kleinrok Z. The influence of antineoplaston A5 on the central dopaminergic structures. Drugs under experimental and clinical research. 1994; 20(4):161-7.
  20. Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs under experimental and clinical research. 1990; 16(7):361-9.
  21. Hendry LB, Muldoon TG, Burzynski SR, Copland JA, Lehner AF. Stereochemical modelling studies of the interaction of antineoplaston A10 with DNA. Drugs under experimental and clinical research. 1987; 13 Suppl 1:77-81.
  22. Liau MC, Szopa M, Burzynski B, Burzynski SR. Chemo-surveillance: a novel concept of the natural defence mechanism against cancer. Drugs under experimental and clinical research. 1987; 13 Suppl 1:71-6.
  23. Liau MC, Szopa M, Burzynski B, Burzynski SR. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy. Drugs under experimental and clinical research. 1987; 13 Suppl 1:61-70.
  24. Khalid M, Burzynski SR. N,N'-disubstituted L-isoglutamines as novel cancer chemotherapeutic agents. Drugs under experimental and clinical research. 1987; 13 Suppl 1:57-60.
  25. Kampalath BN, Liau MC, Burzynski B, Burzynski SR. Chemoprevention by antineoplaston A10 of benzo(a)pyrene-induced pulmonary neoplasia. Drugs under experimental and clinical research. 1987; 13 Suppl 1:51-5.
  26. Ashraf AQ, Liau MC, Kampalath BN, Burzynski SR. Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats. Drugs under experimental and clinical research. 1987; 13 Suppl 1:45-50.
  27. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs under experimental and clinical research. 1987; 13 Suppl 1:37-43.
  28. Lee SS, Burzynski SR. Tissue culture and animal toxicity studies of antineoplaston A5. Drugs under experimental and clinical research. 1987; 13 Suppl 1:31-5.
  29. Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. Drugs under experimental and clinical research. 1987; 13 Suppl 1:17-29.
  30. Lee SS, Mohabbat MO, Burzynski SR. In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3. Drugs under experimental and clinical research. 1987; 13 Suppl 1:13-6.
  31. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs under experimental and clinical research. 1987; 13 Suppl 1:1-11.
  32. Liau MC, Burzynski SR. Altered methylation complex isozymes as selective targets for cancer chemotherapy. Drugs under experimental and clinical research. 1986; 12 Suppl 1:77-86.
  33. Burzynski SR, Mohabbat MO. Chronic animal toxicity studies on antineoplaston A2. Drugs under experimental and clinical research. 1986; 12 Suppl 1:73-5.
  34. Lehner AF, Burzynski SR, Hendry LB. 3-Phenylacetylamino-2,6-piperidinedione, a naturally-occurring peptide analogue with apparent antineoplastic activity, may bind to DNA. Drugs under experimental and clinical research. 1986; 12 Suppl 1:57-72.
  35. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs under experimental and clinical research. 1986; 12 Suppl 1:47-55.
  36. Ashraf AQ, Liau MC, Mohabbat MO, Burzynski SR. Preclinical studies on antineoplaston A10 injections. Drugs under experimental and clinical research. 1986; 12 Suppl 1:37-45.
  37. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs under experimental and clinical research. 1986; 12 Suppl 1:25-35.
  38. Burzynski SR. Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs under experimental and clinical research. 1986; 12 Suppl 1:17-24.
  39. Burzynski SR, Mohabbat MO, Lee SS. Preclinical studies on antineoplaston AS2-1 and antineoplaston AS2-5. Drugs under experimental and clinical research. 1986; 12 Suppl 1:11-6.
  40. Burzynski SR. Antineoplastons: history of the research (I). Drugs under experimental and clinical research. 1986; 12 Suppl 1:1-9.
  41. Burzynski SR, Stolzmann Z, Szopa B, Stolzmann E, Kaltenberg OP. Antineoplaston A in cancer therapy. (I). Physiological chemistry and physics. 1977; 9(6):485-500.
  42. Burzynski SR. Treatments for astrocytic tumors in children: current and emerging strategies. Paediatric drugs. 2006; 8(3):167-78.
  43. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integrative cancer therapies. 2006 Mar; 5(1):40-7.(Link to article – subscription may be required.)
Personal tools